Medindia

X

OTC Markets Group Welcomes PixarBio to OTCQX

Monday, November 28, 2016 Corporate News J E 4
Advertisement

NEW YORK, Nov. 28, 2016 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced PixarBio Corporation (OTCQX: PXRB), a specialty pharmaceutical/biotechnology company, has qualified to trade on the OTCQX® Best Market.  PixarBio upgraded to OTCQX from the OTCQB® Venture Market.  

PixarBio begins trading today on OTCQX under the symbol "PXRB."  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"Trading on OTCQX will enable PixarBio to provide a transparent trading and information experience for investors as it focuses on growing its business and delivering long-term value to shareholders," said Jason Paltrowitz, Executive Vice President of OTC Markets Group.  "We welcome PixarBio to the OTCQX market and wish the company growth and success."

"Trading on OTCQX will provide investors from institutions, individuals, and a wide range of funds the confidence in our accounting and compliance practices.  As industry leaders expected to replace morphine and other addictive opiates in the clinic, PixarBio can now receive investment from a wide range of institutional investors," said Frank Reynolds, CEO of PixarBio.

Burns, Figa & Will, P.C. serves as PixarBio's OTCQX Advisor, responsible for providing professional guidance on OTCQX requirements.

PixarBio Corp. is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain. PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson's disease, and spinal cord injury.  The company's lead product platform, NeuroRelease, is an extended drug release microparticle platform that is non-opiate, non-addictive for post-surgical pain treatment.  In pre-clinical models NeuroRelease has the potential to achieve 6 months of sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain.

About OTC Markets Group Inc.OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.comOTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.Subscribe to the OTC Markets RSS Feed

Media Contact:OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-pixarbio-to-otcqx-300368659.html

SOURCE OTC Markets Group Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Neovasc Receives Regulatory Approval to Initiate T...
S
ABISA Expands with Clients in Switzerland